Treating tuberculosis with spectinamides
Nature Medicine
January 27, 2014
Variations on an old drug generate promising clinical candidates for tuberculosis treatment, reports a study published this week in Nature Medicine. The work, done in mice, validates efforts to repurpose and modify existing drugs to increase their antibacterial efficacy.
Spectinomycin is a naturally found product that acts as an antibiotic, binding to bacterial ribosomes and blocking bacterial protein synthesis; however, it has only modest activity against Mycobacterium tuberculosis. Richard Lee and colleagues synthetically modified spectinomycin to create new drugs called spectinamides, which could potently inhibit M. tuberculosis growth in culture and in infected mice. These drugs selectively inhibited mycobacterial protein synthesis-sparing eukaryotic ribosomes-and avoided removal from the cell by a key drug transporter, thereby increasing mycobacterial killing activity.
doi: 10.1038/nm.3458
Research highlights
-
Nov 26
Evolution: Ancient bird sticks its big beak into the evolutionary recordNature
-
Nov 25
Zoology: Mineral armour discovered in insectsNature Communications
-
Nov 24
Neuroscience: Social isolation evokes craving responses in the human brainNature Neuroscience
-
Nov 20
Archaeology: Transition from tribal to feudal living in 14th century impacted local ecosystemsScientific Reports
-
Nov 18
Ecology: Migration associated with faster pace of lifeNature Communications
-
Nov 17
Gene therapy: Concerns for the long-term safety of AAV gene therapyNature Biotechnology
